Shyr Y - Search Results

1

Longitudinal Cell-Free DNA Analysis in Patients with Small Cell Lung Cancer Reveals Dynamic Insights into Treatment Efficacy and Disease Relapse.

Almodovar K, Iams WT, Meador CB, Zhao Z, York S, Horn L, Yan Y, Hernandez J, Chen H, Shyr Y, Lim LP, Raymond CK, Lovly CM. Almodovar K, et al. Among authors: shyr y. J Thorac Oncol. 2018 Jan;13(1):112-123. doi: 10.1016/j.jtho.2017.09.1951. Epub 2017 Sep 23. J Thorac Oncol. 2018. PMID: 28951314 Free PMC article.

2

Paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a phase II trial.

Johnson DH, Paul DM, Hande KR, Shyr Y, Blanke C, Murphy B, Lewis M, De Vore RF 3rd. Johnson DH, et al. Among authors: shyr y. J Clin Oncol. 1996 Jul;14(7):2054-60. doi: 10.1200/JCO.1996.14.7.2054. J Clin Oncol. 1996. PMID: 8683236 Clinical Trial.

3

Patterns of practice survey for nonsmall cell lung carcinoma in the U.S.

Choy H, Shyr Y, Cmelak AJ, Mohr PJ, Johnson DH. Choy H, et al. Among authors: shyr y. Cancer. 2000 Mar 15;88(6):1336-46. doi: 10.1002/(sici)1097-0142(20000315)88:6<1336::aid-cncr9>3.0.co;2-m. Cancer. 2000. PMID: 10717614

4

A randomized Phase II trial in patients with carcinoma of an unknown primary site.

Dowell JE, Garrett AM, Shyr Y, Johnson DH, Hande KR. Dowell JE, et al. Among authors: shyr y. Cancer. 2001 Feb 1;91(3):592-7. doi: 10.1002/1097-0142(20010201)91:3<592::aid-cncr1039>3.0.co;2-5. Cancer. 2001. PMID: 11169943 Clinical Trial.

5

Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.

Jagasia MH, Langer CJ, Johnson DH, Yunus F, Rodgers JS, Schlabach LL, Cohen AG, Shyr Y, Carbone DP, Devore RF. Jagasia MH, et al. Among authors: shyr y. Clin Cancer Res. 2001 Jan;7(1):68-73. Clin Cancer Res. 2001. PMID: 11205920 Clinical Trial.

6

A training-testing approach to the molecular classification of resected non-small cell lung cancer.

Yamagata N, Shyr Y, Yanagisawa K, Edgerton M, Dang TP, Gonzalez A, Nadaf S, Larsen P, Roberts JR, Nesbitt JC, Jensen R, Levy S, Moore JH, Minna JD, Carbone DP. Yamagata N, et al. Among authors: shyr y. Clin Cancer Res. 2003 Oct 15;9(13):4695-704. Clin Cancer Res. 2003. PMID: 14581339

7

Nuclear survivin as a biomarker for non-small-cell lung cancer.

Lu B, Gonzalez A, Massion PP, Shyr Y, Shaktour B, Carbone DP, Hallahan DE. Lu B, et al. Among authors: shyr y. Br J Cancer. 2004 Aug 2;91(3):537-40. doi: 10.1038/sj.bjc.6602027. Br J Cancer. 2004. PMID: 15266313 Free PMC article.

8

Nuclear survivin predicts recurrence and poor survival in patients with resected nonsmall cell lung carcinoma.

Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, Olson SJ, Andersen JJ, Shyr Y, Carbone DP, Johnson DH, Hallahan DE, Lu B. Shinohara ET, et al. Among authors: shyr y. Cancer. 2005 Apr 15;103(8):1685-92. doi: 10.1002/cncr.20951. Cancer. 2005. PMID: 15742356 Free article.

9

Shared gene expression profiles in individuals with autoimmune disease and unaffected first-degree relatives of individuals with autoimmune disease.

Maas K, Chen H, Shyr Y, Olsen NJ, Aune T. Maas K, et al. Among authors: shyr y. Hum Mol Genet. 2005 May 15;14(10):1305-14. doi: 10.1093/hmg/ddi141. Epub 2005 Apr 6. Hum Mol Genet. 2005. PMID: 15814587

10

Response to combined modality therapy correlates with survival in locally advanced non-small-cell lung cancer.

Kim DW, Shyr Y, Chen H, Akerley W, Johnson DH, Choy H. Kim DW, et al. Among authors: shyr y. Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1029-36. doi: 10.1016/j.ijrobp.2005.03.055. Int J Radiat Oncol Biol Phys. 2005. PMID: 15913910

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

717 results

Search Page